Two days later, Meng Qian's first American assistant, Richard Ralph, got the pharmaceutical company in order. But because Meng Qian does not have an SSN (social security number) for the time being, and the green card has not yet been processed, he must apply for a personal tax number if he wants to set up a company, and he has to run in person.

Fortunately, the local government was very concerned about his investment work, and the problem was quickly dealt with. The "Montson Biopharmaceutical Company" registered by him also successfully submitted an application, with a registered capital of 400 million US dollars, with Meng Qian holding 98%, and Onyx Pharmaceutical also invested 10 million yuan, holding 2% of the shares.

Onix's contribution is largely a friendly support. But the benefits are clear, starting with the location of the new company, which is located in the unused No. 3 area next to the headquarters of Onyx Pharmaceuticals, a suburb south of San Francisco. Covering a vast area.

The area has a three-storey, extraordinarily large building that encompasses the office area, the R&D area and the production plant. It also takes into account the protection of privacy and confidentiality. According to Meng Qian's original casual idea, it was a nonsense to set up a high-end office building in the center of the city.

In developed countries, commercial espionage is on the rise.

No one wants to see the results of their own investment of hundreds of millions or billions, because the confidentiality is not in place to be leaked.

In addition to safety work, a lot of basic equipment is purchased or rented from Onyx, and even related research and management are transferred from Onyx. If you don't know the situation, I'm afraid you still think that Montessori Pharmaceutical is their subsidiary, not like a 2% shareholder.

Of course, there is more than one reason for mutual aid.

For example, Meng Qian also holds a 2.5% stake in Onix Pharmaceutical, making it the sixth largest shareholder.

This kind of cooperative relationship allowed him to avoid countless detours, and the giants also patiently helped him build a foundation. Meng Qian is grateful, and if there is an opportunity in the future, he is happy to cooperate with the two companies...... Of course, at present, Montson Pharmaceutical has not yet entered the eyes of giants.

Let's start with the basics: five new drugs; Stem cell engineering.

The second phase clinical trial of the new drug in China has remarkable efficacy! As Meng Qian, who has personally experienced it, knows that it is absolutely reliable. So he can't wait for them to enter Europe and the United States, and launch a large-scale, three-phase covering different age groups, and if everything goes well, they can be arraigned next year.

After being approved for listing, he will be able to start earning foreign money! It is estimated that the main consumer markets of ED and female cold are concentrated in Europe and the United States, which can provide 80% of sales revenue. Such a large amount of income in Europe and the United States is also the reason why he set up foreign companies and pay attention to this market.

……

After the pharmaceutical company settled in the United States, Meng Qian sorted out his industry.

Meng's Pharmaceutical, also known as Moose, is 70% owned by Meng Qian's wholly-owned offshore company, which also holds 70% of China's Wells Fargo Pharmaceutical. Strictly speaking, they are all subsidiaries of the Marsh Group, so they will be closer in a series of cooperation.

Montson Pharmaceuticals is mainly composed of two divisions: new drugs and stem cell engineering. The new drug is the five new drug technologies he prescribed, and the drug has been successful, but due to secular procedures, the drug needs clinical trials to verify the results, and the consumption of funds is mainly here.

Stem cell engineering is more complicated, and its basic work such as culture and differentiation are handed over to China, while animal experiments and clinical experiments are left here, and the two-pronged approach is used to save time. Based on the results of the laboratory, it is relatively smooth in China, while it is still confused abroad.

"This department needs to be managed competently." Meng Qian was talking to Zhang Dongliang on the phone, and he needed to bring this expert over—including his friends here.

"I'll be able to pass the day after tomorrow." Zhang Dongliang is also refreshing, the domestic basic work will not be fruitful for a while and a half, and he is looking forward to the use of stem cell technology.

"Waiting for you." Meng Qian expects that there is too much work at present, and he can't be busy alone, and what he can share with his subordinates is basically arranged.

A few days later, Mr. Zhang, Mr. Xu, and his assistants arrived in San Francisco.

Meng Qian drove to pick them up, and on the way back to the hotel, Zhang Dongliang was talking on the phone with his mobile phone, and his fluent English made Meng Qian not understand.

"Awesome, Lao Zhang!" Meng Qian has seen it, Zhang Dongliang is a northerner, and the pronunciation of Mandarin is a bit heavy, but he didn't expect to speak English so slippery.

"I was a graduate student at UCSF." Zhang Dongliang recalled, "It was a university that was only for graduate students and above, and there were a lot of people. ”

"Can you still contact these masters?" Meng Qian cares about this, and what is lacking in stem cell engineering is not money, but researchers with real materials.

Zhang Dongliang said: "Before I came, I sent a lot of emails and phone calls, and many people were interested in hearing about our current results. But whether you can enter the pit or not depends on the level. ”

"Well done! I will send you a bonus in return. Meng Qian was finally relieved, he was not afraid of the lack of technical strength, he was afraid that others would think that the temple was small and could not accommodate the big Bodhisattva.

Facts have proved that Lao Zhang is indeed capable.

His circle of friends includes whites, Hispanics, etc., who are older, and they are all talents in the biomedical field, and they all work in research institutes and large companies, and they all have great backgrounds. Compared with Zhang Dongliang, who returned to China for development after completing his studies but did not meet talents, it is really embarrassing.

"At present, we have made great breakthroughs in the rapid cultivation of stem cells and the differentiation of designated inducers, and papers are also being written. I came here this time because my investor and technology partner, Mr. Meng, hopes to promote the technology quickly and on a large scale. ”

Lao Zhang spoke eloquently in English, and Meng Qian struggled to understand, especially the professional terms, he lacked vocabulary.

However, under Zhang Dongliang's translation, Meng Qian still successfully expressed his technical thinking and ideas clearly, which also made the expressions of the experts present change, from mistaking him for Lao Zhang's son at the beginning, to the current investor and technology master, and completed a wonderful transition on his face.

"Gentlemen, are you interested?" Zhang Dongliang finally said.

The experts looked at each other and saw the expectation and excitement from it...... Meng Qian understands these people very well, and the pursuit of technology and honor is above all else.

So there weren't many questions, and replies came two days later.

As for their original positions, those who can take on the same position will take on the job, and those who can't will change jobs. The cost of digging the foot of the wall can be afforded by the currently well-funded Montessori Pharmaceutical.

He also took a personal tour of the company: "I'm going to invest $200 million in the first phase of this project, and if it goes well, there will be more grants." ”

After everyone knew Meng Qian's origins, they no longer doubted his financial ability - a billionaire with a net worth of more than 10 billion, this investment had no pressure on him.

Then they started talking about technology.

As long as there is enough animal test data to back it up, the FDA should approve them for Phase 1 clinical trials, which will be used to validate the theory, and if the trial goes well, the Phase 2 and 3 will begin. After four or five years of overall consumption, wealth and Nobel Prizes are not a problem.

But no one can predict what problems and difficulties will be encountered on the way.

Meng Qian excavated as much technology as possible in his head and perfected it in all aspects. But he can't fully devote his time and energy to this area, so he also wants the experts to use their abilities to compensate for his weaknesses - which is why he is willing to pay a high price to dig into the wall.

After the stem cell project was in place, Meng Qian dealt with the problem of new drugs.

Xu Peng, who is in the same company, although he is not like Zhang Dongliang who holds the Nobel Prize project, he may have become famous earlier!

Because of the research and clinical use of X and a number of new drugs, its powerful effect has made the media shake out, and it has been spread in a short time! The papers they have written have also been included in foreign professional magazines, and the English version is expected to be published next month!

Professional papers are an important guarantee to support its theory and efficacy, and on the other hand, the actual clinical effect is also the focus of determining the prospect. Now that both of these have achieved good results and are about to spread to the United States, they will make their development path smoother.

In addition, Xu Peng also brought a piece of news: "After the results were published in domestic magazines and newspapers, the pharmaceutical giant Eli Lilly approached us. ”

"What are they going to do?" Meng Qian asked.

"They are very interested in ED drugs for men and are willing to buy our related technology at a high price," Xu said. ”

"Acquisition?" Meng Qian pondered that because of the investment in stem cells and new drug clinics, the demand for funds is very large, and the current 400 million is far from enough.

If stem cells want to be industrialized on a large scale, the investment will be more than 5 billion US dollars.

Although the research and development of new drugs can be saved, if the funds are abundant, wouldn't it be better to engage in research with great fanfare?

Meng Qian currently owns $2.5 billion worth of shares in Onyx Pharmaceutical, but the company's stock price is rising, and it is too much of a loss to cash out at this time - he has just enjoyed the pleasure of being a major shareholder of a giant company, and they have helped Montson Pharmaceuticals a lot.

The shares cannot be cashed out for the time being, and the funds on hand are insufficient.

It seems that a child is going to be sold to feed a larger family. Meng Qian originally used the new drug as a side business to make money, slowly operating to make money and selling it for cash at one time, as long as it helped him to brush money, he didn't mind which one to take. At the moment, the focus is on asking for money to develop.

In medicine and pharmaceuticals, the child he can't sell (main business) is stem cells!

He is going to give priority to feeding them.

Therefore, if Meng Qian considered that the price was negotiable, he would sell it, and as for the price...... Meng Qian said casually: "The asking price is 5 billion US dollars, of which at least 2 billion in cash!" ”

Xu Peng is not in business, so he doesn't feel anything wrong: "I will notify the country." ”